首页
>
期刊首页
>
中国医学科学杂志(英文版)
>
2001年4期
>
POTENTIATION OF DOCETAXEL ANTITUMOR ACTIVITY BY BATIMASTAT AGAINST MOUSE FORESTOMACH CARCINOMA
POTENTIATION OF DOCETAXEL ANTITUMOR ACTIVITY BY BATIMASTAT AGAINST MOUSE FORESTOMACH CARCINOMA
摘要
Objective. To improve the treatment of tumors, we studied the combined effects of docetaxel and batimastat(BB-94) on mouse forestomach carcinoma (MFC), and compared them with doxorubicin.Methods and results. In vitro, growth curve analysis, MTF assay and clonogenic assay used to determine thecvtotoxic effect of cocetaxel or/and BB-94 on MFC cell showed that docetaxel but not BB-94 had a significantcytotoxicity, and the effect of docetaxel wasn't enhanced by BB-94. In early stage MFC tumor model, obviousantitumor effect of docetaxel or doxorubicin given i. v. at maximum tolerated dose (MTD, docetaxel: 20mg/kg;doxorubicin: 6mg/kg) every 4 days for 3 injections (q4d x3), even that of BB-94 (30mg/kg i. p. qd ×20)was observed. Tumorgrowth inhibition was greater for docetaxel-batimastat (96.0%) than for doxorubicin - batimas-tat (88.0%), docetaxel (89.0%), doxorubicin (68.0%) and BB-94 (33.0%), and the effect of docetaxelcould be potentiated by BB-94. Docetaxel also showed activity against advanced stage MFC tumor in dose - depen-dent manner, and was more effective at MTD than doxorubicin with 4/5 regressions, 46.5 days tumor growth de-lay and 2.81og10 turmor cell kill.Conclusion. O ur results suggest that in the MFC model with dose and schedule used, docetaxel is an effec-tive cytotoxic new drug against MFC tumor and BB-94 enchances the antitumor activity of docetaxel.
作者单位:
Department of Clinical Pharmacology, North Taiping Road Hospital, Beijing 100039
年,卷(期):
2001, 16(4)
分类号:
R73
机标分类号:
X13
R73
在线出版日期:
2004年2月6日